Target type: molecularfunction
Combining with a neuropeptide to initiate a change in cell activity. [GOC:ai]
Neuropeptide receptor activity encompasses the intricate molecular processes by which cells receive and interpret signals transmitted by neuropeptides. These signaling molecules, produced by neurons, play pivotal roles in regulating diverse physiological functions across the nervous system and beyond. The activity involves a series of events initiated by the binding of a neuropeptide to its cognate receptor, a transmembrane protein embedded within the cell membrane. This binding event triggers conformational changes in the receptor, leading to the activation of downstream signaling pathways. These pathways can involve a cascade of intracellular events, including alterations in protein phosphorylation, changes in ion channel permeability, and modulation of gene expression. The specific molecular mechanisms underlying neuropeptide receptor activity vary depending on the receptor type and the signaling cascade involved. However, all neuropeptide receptors share the fundamental role of converting extracellular neuropeptide signals into intracellular responses that ultimately influence cellular function and behavior. This intricate molecular machinery underpins the diverse roles of neuropeptides in regulating processes such as neurotransmission, hormone release, pain perception, appetite, and stress responses.'
"
Protein | Definition | Taxonomy |
---|---|---|
Neuromedin-U receptor 1 | A neuromedin-U receptor 1 that is encoded in the genome of human. [PRO:WCB, UniProtKB:Q9HB89] | Homo sapiens (human) |
Bombesin receptor subtype-3 | A bombesin receptor subtype-3 that is encoded in the genome of human. [PRO:WCB, UniProtKB:P32247] | Homo sapiens (human) |
Neuropeptide Y receptor type 1 | A neuropeptide Y receptor type 1 that is encoded in the genome of human. [PRO:WCB, UniProtKB:P25929] | Homo sapiens (human) |
Neuromedin-B receptor | A neuromedin-B receptor that is encoded in the genome of human. [PRO:WCB, UniProtKB:P28336] | Homo sapiens (human) |
Neuromedin-U receptor 2 | A neuromedin-U receptor 2 that is encoded in the genome of human. [PRO:CNx, Reactome:R-HSA-964816] | Homo sapiens (human) |
Neuropeptide FF receptor 2 | A neuropeptide FF receptor 2 that is encoded in the genome of human. [PRO:WCB, UniProtKB:Q9Y5X5] | Homo sapiens (human) |
Neuropeptide FF receptor 1 | A neuropeptide FF receptor 1 that is encoded in the genome of human. [PRO:WCB, UniProtKB:Q9GZQ6] | Homo sapiens (human) |
Melanin-concentrating hormone receptor 1 | A melanin-concentrating hormone receptor 1 that is encoded in the genome of human. [PRO:WCB, UniProtKB:Q99705] | Homo sapiens (human) |
KiSS-1 receptor | A KiSS-1 receptor that is encoded in the genome of human. [PRO:WCB, UniProtKB:Q969F8] | Homo sapiens (human) |
Neuropeptide S receptor | A neuropeptide S receptor that is encoded in the genome of human. [PRO:WCB, UniProtKB:Q6W5P4] | Homo sapiens (human) |
Neuropeptides B/W receptor type 1 | A neuropeptides B/W receptor type 1 that is encoded in the genome of human. [PRO:WCB, UniProtKB:P48145] | Homo sapiens (human) |
Gastrin-releasing peptide receptor | A gastrin-releasing peptide receptor that is encoded in the genome of human. [PRO:WCB, UniProtKB:P30550] | Homo sapiens (human) |
Orexin receptor type 2 | An orexin receptor type 2 that is encoded in the genome of human. [PRO:DNx, UniProtKB:O43614] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
benextramine | benextramine: RN given refers to parent cpd | ||
omeprazole | 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5. omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole. Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. | aromatic ether; benzimidazoles; pyridines; sulfoxide | |
synephrine | ethanolamines; phenethylamine alkaloid; phenols | alpha-adrenergic agonist; plant metabolite | |
benzethonium chloride | benzethonium chloride : A (synthetic) quaternary ammonium salt that is benzyldimethylamine in which the nitrogen is quaternised by a 2-{2-[p-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy}ethyl group, with chloride as the counter-ion. An antiseptic and disinfectant, it is active against a broad spectrum of bacteria, fungi, moulds and viruses. | aromatic ether; chloride salt; quaternary ammonium salt | antibacterial agent; antifungal agent; antiseptic drug; antiviral agent; disinfectant |
omeprazole sulfide | omeprazole sulfide: omeprazole metabolite; structure given in first source | benzimidazoles | |
harmalan | harmalan: structure given in first source | harmala alkaloid | |
1-(3-(4-chlorobenzoyl)propyl)-4-hydroxy-4-(4-chlorophenyl)piperidine | 1-(3-(4-chlorobenzoyl)propyl)-4-hydroxy-4-(4-chlorophenyl)piperidine: RN given refers to parent cpd | ||
1-methyl-6-methoxy-dihydro-beta-carboline | |||
sb 408124 | SB 408124: a hypocretin receptor type 1 (HcrtR1) antagonist | organohalogen compound; quinolines | |
rutin | Hydroxyethylrutoside: Monohydroxyethyl derivative of rutin. Peripheral circulation stimulant used in treatment of venous disorders. | disaccharide derivative; quercetin O-glucoside; rutinoside; tetrahydroxyflavone | antioxidant; metabolite |
harmine | harmine : A harmala alkaloid in which the harman skeleton is methoxy-substituted at C-7. Harmine: Alkaloid isolated from seeds of PEGANUM HARMALA; ZYGOPHYLLACEAE. It is identical to banisterine, or telepathine, from Banisteria caapi and is one of the active ingredients of hallucinogenic drinks made in the western Amazon region from related plants. It has no therapeutic use, but (as banisterine) was hailed as a cure for postencephalitic PARKINSON DISEASE in the 1920's. | harmala alkaloid | anti-HIV agent; EC 1.4.3.4 (monoamine oxidase) inhibitor; metabolite |
bibp 3226 | BIBP 3226: a selective non-peptide neuropeptide Y Y1 receptor antagonist; structure given in first source; BIBP-3435 is the S-enantiomer | ||
cgp 71683 a | naphthalenes; sulfonic acid derivative | ||
sb 334867-a | 1-(2-methylbenzoxazol-6-yl)-3-(1,5)naphthyridin-4-yl urea: selective OX1 receptor antagonist | naphthyridine derivative | |
gw 803430 | |||
pd 176252 | PD 176252: a non-peptide gastrin-releasing peptide (BB2) receptor antagonist; structure in first source | ||
phenylalanyl-leucyl-phenylalanyl-glutaminyl-prolyl-glutaminyl-arginyl-phenylalaninamide | |||
t-226296 | T-226296: structure in first source | ||
jnj 10397049 | JNJ 10397049: a selective orexin receptor-2 antagonist | ||
n-(4-((4-(dimethylamino)quinazolin-2-yl)amino)cyclohexyl)-3,4-difluorobenzamide hydrochloride | |||
pd 168368 | PD 168368: a neuromedin B receptor antagonist; structure in first source | ||
4-n-butyl-1-(4-(2-methylphenyl)-4-oxo-1-butyl)-piperidine hydrogen chloride | |||
bms 193885 | |||
fmrfamide | FMRFamide: A molluscan neuroactive peptide which induces a fast excitatory depolarizing response due to direct activation of amiloride-sensitive SODIUM CHANNELS. (From Nature 1995; 378(6558): 730-3) | ||
sb674042 | SB674042: nonpeptide antagonist to the human orexin-1 receptor; structure in first source | ||
neuromedin u 8 | |||
tcs ox2 29 | |||
sha 68 | |||
snap7941 | SNAP7941: structure in first source | ||
neuropeptide y (24-36) amide, n-acetyl-(leu(28,31))- | neuropeptide Y (24-36) amide, N-acetyl-(Leu(28,31))-: a presynaptic (Y2) receptor-specific neuropeptide Y analog | ||
neuropeptide y | Neuropeptide Y: A 36-amino acid peptide present in many organs and in many sympathetic noradrenergic neurons. It has vasoconstrictor and natriuretic activity and regulates local blood flow, glandular secretion, and smooth muscle activity. The peptide also stimulates feeding and drinking behavior and influences secretion of pituitary hormones. | ||
bombesin | |||
lu aa33810 | |||
almorexant | almorexant: a dual orexin receptor antagonist for treatment of insomnia | isoquinolines | |
suvorexant | suvorexant : An aromatic amide obtained by formal condensation of the carboxy group of 5-methyl-2-(2H-1,2,3-triazol-2-yl)benzoic acid with the secondary amino group of 5-chloro-2-[(5R)-5-methyl-1,4-diazepan-1-yl]-1,3-benzoxazole. An orexin receptor antagonist used for the management of insomnia. suvorexant: an orexin receptor antagonist; structure in first source | 1,3-benzoxazoles; aromatic amide; diazepine; organochlorine compound; triazoles | central nervous system depressant; orexin receptor antagonist |
mk-6096 | MK-6096: antagonist of orexin receptors 1 and 2; structure in first source | ||
sb 649868 | N-((1-((5-(4-fluorophenyl)-2-methyl-4-thiazolyl)carbonyl)-2-piperidinyl)methyl)-4-benzofurancarboxamide: antagonist of both orexin 1 and orexin 2 receptors; for treating insomnia; structure in first source | ||
kisspeptin-10 protein, human | |||
act-462206 | ACT-462206: an antagonist of both orexin 1 and oxexin 2 receptors; structure in first source | ||
oroxin b | |||
gsk 1059865 | |||
nitd 609 | NITD 609: an antimalarial and coccidiostat; structure in first source | ||
5-chloro-2-(3,5-dimethylphenyl)-4-(4-methoxyphenoxy)-3-pyridazinone | aromatic ether | ||
tak-683 | TAK-683: has antineoplastic activity | ||
AZD1979 | AZD1979 : A carboxamide resulting from the formal condensation of the carboxy group of 5-(p-methoxyphenyl)-1,3,4-oxadiazole-2-carboxylic acid with the amino group of 3-phenoxyazetidine and in which the phenoxy group has been substituted at the para- position by a 2-oxa-6-azaspiro[3.3]heptan-6-ylmethyl group. It is a melanin concentrating hormone receptor 1 (MCHr1) antagonist. AZD1979: an antagonist of melanin concentrating hormone receptor 1; structure in first source | aromatic ether; azaspiro compound; carboxamide; N-acylazetidine; oxadiazole; oxaspiro compound; oxetanes | melanin-concentrating hormone receptor antagonist |
mk 5046 | |||
inosine | 5-chloro-2-(9H-fluoren-9-yl)-4-(4-methoxyphenoxy)pyridazin-3(2H)-one: an NPBWR1 antagonist; structure in first source | ||
RF9 | dipeptide | kisspeptin receptor agonist; neuropeptide FF receptor agonist; neuropeptide FF receptor antagonist | |
act-335827 | |||
orexin-a |